EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Exploring Clearance Pathways for GalNAc–siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications

Madeline C Tompach iD, Kevin Craig, Shrutokirti De

Nucleic Acid Therapeutics · 01.08.2026 · 36 (4) · 177-186

DOI: 10.1177/21593337261457402 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 09.06.2026. Verfasst von Madeline C Tompach und 2 weiteren Autor:innen. Beteiligte Einrichtung: ADME, Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: RNA, Small Interfering, Acetylgalactosamine, Liver Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small interfering RNA (siRNA) represents a transformative therapeutic class that enables precise gene silencing through RNA interference (RNAi). N-acetyl galactosamine (GalNAc)-conjugated siRNAs have achieved remarkable clinical success with six FDA-approved therapeutics targeting liver diseases. Following subcutaneous administration, GalNAc–siRNAs rapidly accumulate in hepatocytes via asialoglycoprotein receptor (ASGPR)-mediated endocytosis and are sequestered within endolysosomal compartments, creating an intracellular depot that sustains therapeutic effects for weeks to months. While RNAi-mediated degradation and nuclease metabolism contribute to siRNA clearance, the detection of full-length, active siRNA in circulation long after dosing suggests alternative clearance mechanisms exist. This review examines the pharmacokinetic properties and intracellular trafficking of GalNAc–siRNA, with particular focus on underexplored clearance pathways from hepatocytes. We discuss potential mechanisms including endosomal recycling, efflux via exosomes and lysosomal exocytosis that may facilitate siRNA redistribution from tissues to circulation. Understanding these clearance mechanisms could enable correlation of plasma and tissue drug concentrations, reduce preclinical animal use, inform clinical dosing strategies and guide the design of next-generation siRNA therapeutics with optimized tissue residence time and enhanced therapeutic durability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingAcetylgalactosamineLiver DiseasesHumansAnimalsHepatocytesRNA InterferenceEndosomesAsialoglycoprotein ReceptorLysosomesEndocytosisExosomes

Stichwörter der Autor:innen

GalNAc–siRNAendolysosomal pathwayintracellular siRNA distributionredistributionsiRNA intracellular clearancesiRNA therapeutics

Substanzen

RNA, Small InterferingAcetylgalactosamineAsialoglycoprotein Receptor

Autor:innen und Institutionen

  • ADME, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Lilly Genetic Medicines RNA Pharmacology, Eli Lilly and Company, Boston, Massachusetts, USA.

ORCID-Profile: Madeline C Tompach

Förderung

  • Eli Lilly and Company

Zitieren

APA

Tompach, M. C., Craig, K., & De, S. (2026). Exploring Clearance Pathways for GalNAc–siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications. Nucleic Acid Therapeutics, 36(4), 177-186. https://doi.org/10.1177/21593337261457402

Vancouver

Tompach MC, Craig K, De S. Exploring Clearance Pathways for GalNAc–siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications. Nucleic Acid Therapeutics. 2026;36(4):177-186. doi:10.1177/21593337261457402

BibTeX
@article{Tompach2026,
  author = {Tompach, Madeline C and Craig, Kevin and De, Shrutokirti},
  title = {Exploring Clearance Pathways for GalNAc–siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications},
  journal = {Nucleic Acid Therapeutics},
  year = {2026},
  volume = {36},
  number = {4},
  pages = {177--186},
  doi = {10.1177/21593337261457402}
}
Kostenlos starten →